Table 2.
Comparison of “active job” and “no job” groups regarding the achieved improvements in health-related quality of life and major symptoms of Parkinson's disease after bilateral subthalamic deep brain stimulation.
| Active job group (at the time of surgery) | No job group (at the time of surgery) |
Between groups (Mann-Whitney) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Percentile 25 |
Percentile 75 |
Mean | Standard deviation |
Friedman test (within group) |
Median | Percentile 25 |
Percentile 75 |
Mean | Standard deviation |
Friedman test (within group) |
|||
| EQ-5D | Baseline | 0.477 | 0.116 | 0.605 | 0.391 | 0.307 | 0.429 | 0.255 | 0.666 | 0.411 | 0.308 | 0.779 | ||
| 1 year | 0.660 | 0.530 | 0.770 | 0.661 | 0.163 | <0.001 | 0.507 | 0.439 | 0.691 | 0.543 | 0.183 | <0.001 | 0.035 | |
| 2 years | 0.687 | 0.620 | 0.811 | 0.710 | 0.138 | 0.587 | 0.482 | 0.742 | 0.606 | 0.191 | 0.045 | |||
|
| ||||||||||||||
| EQ-5D VAS | Baseline | 70 | 55 | 80 | 68.1 | 14.0 | 67 | 50 | 79 | 64.4 | 17.7 | 0.495 | ||
| 1 year | 84 | 71 | 93 | 80.4 | 14.9 | <0.001 | 70 | 60 | 82 | 69.4 | 16.2 | <0.001 | 0.037 | |
| 2 years | 88 | 77 | 90 | 81.2 | 15.0 | 73 | 60 | 80 | 71.5 | 14.9 | 0.021 | |||
|
| ||||||||||||||
| SES | Baseline | 70 | 60 | 80 | 71.5 | 11.8 | 70 | 65 | 80 | 71.0 | 15.5 | 0.845 | ||
| 1 year | 80 | 75 | 90 | 82.0 | 11.5 | <0.001 | 80 | 70 | 80 | 76.5 | 11.8 | 0.002 | 0.153 | |
| 2 years | 80 | 80 | 90 | 81.5 | 11.4 | 70 | 59 | 80 | 68.9 | 11.9 | 0.001 | |||
|
| ||||||||||||||
| UPDRS-III | Baseline | 25 | 22 | 29 | 25.6 | 6.3 | 24 | 19 | 30 | 23.9 | 7.2 | 0.506 | ||
| 1 year | 22 | 18 | 26 | 22.1 | 5.3 | <0.001 | 22 | 18 | 27 | 22.0 | 6.3 | <0.001 | 0.839 | |
| 2 years | 22 | 17 | 24 | 20.8 | 5.0 | 20 | 17 | 26 | 20.8 | 6.4 | 0.860 | |||
|
| ||||||||||||||
| UPDRS-II | Baseline | 15 | 14 | 19 | 15.4 | 4.7 | 15 | 12 | 19 | 14.9 | 5.3 | 0.724 | ||
| 1 year | 13 | 10 | 17 | 12.9 | 4.3 | <0.001 | 16 | 10 | 19 | 14.8 | 6.3 | <0.001 | 0.243 | |
| 2 years | 12 | 9 | 16 | 12.2 | 4.9 | 15 | 11 | 19 | 15.1 | 6.9 | 0.116 | |||
|
| ||||||||||||||
| MADRS | Baseline | 7 | 6 | 10 | 7.9 | 3.8 | 8 | 5 | 9 | 7.9 | 3.2 | 0.744 | ||
| 1 year | 6 | 5 | 9 | 6.8 | 2.6 | 0.020 | 7 | 5 | 10 | 7.4 | 3.5 | 0.590 | 0.395 | |
| 2 years | 5 | 5 | 7 | 5.7 | 1.6 | 7 | 5 | 10 | 7.4 | 3.2 | 0.066 | |||
|
| ||||||||||||||
| MDRS | Baseline | 135 | 130 | 139 | 134.5 | 5.6 | 136 | 130 | 143 | 136.1 | 6.2 | 0.342 | ||
| 1 year | 134 | 128 | 136 | 133.1 | 5.8 | 0.246 | 133 | 127 | 140 | 133.1 | 6.2 | 0.215 | 0.903 | |
| 2 years | 134 | 130 | 137 | 132.7 | 6.3 | 133 | 127 | 140 | 133.2 | 6.2 | 0.839 | |||
|
| ||||||||||||||
| LED | Baseline | 905.0 | 780.0 | 1060.0 | 972.9 | 379.2 | 950 | 750 | 1000 | 925.0 | 265.3 | 0.903 | ||
| 1 year | 475.0 | 325.0 | 700.0 | 535.1 | 315.0 | <0.001 | 509.0 | 400.0 | 678.5 | 559.7 | 216.6 | <0.001 | 0.447 | |
| 2 years | 500.0 | 375.0 | 700.0 | 552.5 | 250.5 | 525.0 | 406.0 | 700.0 | 575.0 | 186.5 | 0.463 | |||
Friedman test was used to evaluate within-group changes (comparison of baseline values with 1st year and 2nd year of follow-up). Mann-Whitney test was applied to detect between-groups differences (e.g., comparison of “active job” group versus “no job” group).
HYS = Hoehn-Yahr Stages; LED = levodopa equivalent dosage; MADRS = Montgomery-Asberg Depression Rating Scale; MDRS = Mattis Dementia Rating Scale; SES = Schwab and England Scale; UPDRS-II = Activities of Daily Living (Part II of UPDRS); UPDRS = Unified Parkinson's Disease Rating Scale; UPDRS-III = Motor Examination (Part III of UPDRS); EQ-5D = EuroQol Instrument.